Sep 11, 2020
AstraZeneca PLC is a London based, British-Swedish multinational pharmaceutical and biopharmaceutical. As the COVID-19 pandemic broke out in 2020, AstraZeneca announced that they are working together with GlaxoSmithKline and the University of Cambridge to create a new laboratory that would be able to conduct as many as 30,000 tests per day. In addition to this, in June 2020, the company announced that they are working on developing potential vaccines.
UK’s NHS received 100 million doses in June 2020, and then Oxford University signed an agreement to develop and produce the vaccine for the USA. AstraZeneca eventually proceeded to provide 300 million doses to the USA. However, in September 2020, the company announced that Phase 3 of the vaccine trials had been paused as a patient in the UK had an adverse reaction to the drug. The next day the company said it would resume the trials.
At the heart of our core values is to “follow the science” and we are committed to adhere to the highest scientific and clinical standards as we research a potential #COVID19 vaccine. @Sanofi will you join us as #WeStandWithScience? https://t.co/uEaOpNBba8 pic.twitter.com/WgJestzs3D
— AstraZeneca (@AstraZeneca) September 8, 2020
AstraZeneca announced in a recent statement, “Standard review process triggered a pause to vaccination to allow the review of safety data.” Pharma stocks over 6% once the pause was announced. The participant who triggered the pause was a British woman who had a neurological reaction called transverse myelitis that caused the spinal inflammatory disorder. The woman’s condition was serious, but it has been reported that she is improving.
Currently, the company is overseeing the safety components of the trials and the vaccine.